Inactive Instrument

Insiders Arch Biopartners Inc. Other OTC

Equities

Arch Biopartners Names Strategic Advisor, Clinical Trials	05/22/05	MT
Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate	05/22/05	CI
Arch Biopartners : named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange Companies.	25/22/25	PU
Arch Biopartners Inc. Announces Stepping Down of Adrian Haigh from the Board of Directors	10/21/10	CI
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients	26/21/26	CI
Arch Biopartners Appoints Patrick Vink to Board of Directors	12/16/12	CI
Arch Biopartners Appoints Adrian Haigh to Board of Directors as an Interim Director	21/14/21	CI
Arch Biopartners Inc Appoints Claude Allary as an Interim Director	17/14/17	CI

No results for this search